Chinese therapeutics medicine developer Thousand Oaks Biopharmaceuticals Co. announced yesterday that they have completed a RMB300 million (US$43.61 million) series A round of financing, led by New Alliance Capital, according to a company statement.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?